Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186304032> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3186304032 endingPage "S334" @default.
- W3186304032 startingPage "S334" @default.
- W3186304032 abstract "With the recent development of immune checkpoint inhibitors (ICIs), the use of ICIs for managing postoperative recurrence of non-small cell lung cancer (NSCLC) is increasing. In this study, we retrospectively examined the postoperative recurrence cases of NSCLC where nivolumab was used for treatment and evaluated the prognostic factors. Patients who received nivolumab monotherapy for postoperative recurrence of NSCLC from March 2016 to September 2020 in our department were included in this study. Information on age, sex, performance status (PS) at the time of administration, histological type, recurrence type, presence/absence of adverse events, number of administrations, and outcomes was retrieved from the medical records and analyzed retrospectively. The survival was estimated using the Kaplan-Meier method, and comparisons between groups were performed using the log-rank method. Twenty patients were treated with nivolumab monotherapy for postoperative recurrence of NSCLC within the study timeframe. The average age of the 16 men and 4 women was 67.5 years. Histologically, there were 13 cases of adenocarcinoma, 3 cases of squamous cell carcinoma, 2 cases of pleomorphic carcinoma, and 2 cases of adenosquamous cell carcinoma. The median number of doses for nivolumab was 6.5. The recurrence was in the form of only thoracic cavity recurrence in 9 cases and brain metastases in 2 cases. Adverse events were observed in 5 cases. PS were 0, 1, 2, and 3, in 7, 5, 5, and 3 cases, respectively. The median survival time was 273 days. PS0 at the time of administration had a better prognosis than PS1 or higher (median overall survival for PS0: 918 days, PS1: 185 days, PS2: 132 days, and PS3: 69 days, p=0.001). We concluded that, in patients treated with nivolumab monotherapy for postoperative recurrence of NSCLC, a good PS at the time of nivolumab administration was associated with a good prognosis and increased overall survival." @default.
- W3186304032 created "2021-08-02" @default.
- W3186304032 creator A5006864485 @default.
- W3186304032 creator A5017568301 @default.
- W3186304032 creator A5027335747 @default.
- W3186304032 creator A5029193270 @default.
- W3186304032 creator A5039150500 @default.
- W3186304032 creator A5054136956 @default.
- W3186304032 creator A5055514477 @default.
- W3186304032 creator A5056322971 @default.
- W3186304032 creator A5085008694 @default.
- W3186304032 date "2021-07-01" @default.
- W3186304032 modified "2023-10-03" @default.
- W3186304032 title "P8-3 Prognostic factors for nivolumab monotherapy in postoperative recurrence of non-small cell lung cancer" @default.
- W3186304032 doi "https://doi.org/10.1016/j.annonc.2021.05.687" @default.
- W3186304032 hasPublicationYear "2021" @default.
- W3186304032 type Work @default.
- W3186304032 sameAs 3186304032 @default.
- W3186304032 citedByCount "0" @default.
- W3186304032 crossrefType "journal-article" @default.
- W3186304032 hasAuthorship W3186304032A5006864485 @default.
- W3186304032 hasAuthorship W3186304032A5017568301 @default.
- W3186304032 hasAuthorship W3186304032A5027335747 @default.
- W3186304032 hasAuthorship W3186304032A5029193270 @default.
- W3186304032 hasAuthorship W3186304032A5039150500 @default.
- W3186304032 hasAuthorship W3186304032A5054136956 @default.
- W3186304032 hasAuthorship W3186304032A5055514477 @default.
- W3186304032 hasAuthorship W3186304032A5056322971 @default.
- W3186304032 hasAuthorship W3186304032A5085008694 @default.
- W3186304032 hasBestOaLocation W31863040321 @default.
- W3186304032 hasConcept C121608353 @default.
- W3186304032 hasConcept C126322002 @default.
- W3186304032 hasConcept C141071460 @default.
- W3186304032 hasConcept C143998085 @default.
- W3186304032 hasConcept C195910791 @default.
- W3186304032 hasConcept C197934379 @default.
- W3186304032 hasConcept C2776256026 @default.
- W3186304032 hasConcept C2776512503 @default.
- W3186304032 hasConcept C2777546739 @default.
- W3186304032 hasConcept C2777701055 @default.
- W3186304032 hasConcept C2780030458 @default.
- W3186304032 hasConcept C2781182431 @default.
- W3186304032 hasConcept C71924100 @default.
- W3186304032 hasConcept C90924648 @default.
- W3186304032 hasConceptScore W3186304032C121608353 @default.
- W3186304032 hasConceptScore W3186304032C126322002 @default.
- W3186304032 hasConceptScore W3186304032C141071460 @default.
- W3186304032 hasConceptScore W3186304032C143998085 @default.
- W3186304032 hasConceptScore W3186304032C195910791 @default.
- W3186304032 hasConceptScore W3186304032C197934379 @default.
- W3186304032 hasConceptScore W3186304032C2776256026 @default.
- W3186304032 hasConceptScore W3186304032C2776512503 @default.
- W3186304032 hasConceptScore W3186304032C2777546739 @default.
- W3186304032 hasConceptScore W3186304032C2777701055 @default.
- W3186304032 hasConceptScore W3186304032C2780030458 @default.
- W3186304032 hasConceptScore W3186304032C2781182431 @default.
- W3186304032 hasConceptScore W3186304032C71924100 @default.
- W3186304032 hasConceptScore W3186304032C90924648 @default.
- W3186304032 hasLocation W31863040321 @default.
- W3186304032 hasOpenAccess W3186304032 @default.
- W3186304032 hasPrimaryLocation W31863040321 @default.
- W3186304032 hasRelatedWork W1748335368 @default.
- W3186304032 hasRelatedWork W1964681864 @default.
- W3186304032 hasRelatedWork W2018380129 @default.
- W3186304032 hasRelatedWork W2070385249 @default.
- W3186304032 hasRelatedWork W2359279895 @default.
- W3186304032 hasRelatedWork W2473322630 @default.
- W3186304032 hasRelatedWork W2475257193 @default.
- W3186304032 hasRelatedWork W2770647538 @default.
- W3186304032 hasRelatedWork W2962961055 @default.
- W3186304032 hasRelatedWork W3097428643 @default.
- W3186304032 hasVolume "32" @default.
- W3186304032 isParatext "false" @default.
- W3186304032 isRetracted "false" @default.
- W3186304032 magId "3186304032" @default.
- W3186304032 workType "article" @default.